BLOOMFIELD, N.J., Oct. 11 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL ) today announced that the Company was presented with a "Pioneer Award" from the Mesothelioma Applied Research Foundation (MARF) at its Second International Symposium on Malignant Mesothelioma, held last week in Las Vegas. The Pioneer Award was introduced by MARF this year to honor companies that have made substantial contributions to the field of mesothelioma research. "It is a great honor to receive one of the first MARF Pioneer Awards," stated Kuslima Shogen, Chief Executive Officer of Alfacell, who accepted the award on behalf of the Company. "Even greater was the opportunity to meet many patients and others who have lost loved ones to mesothelioma. It was humbling to receive their praise, and inspiring to witness their grace and determination to conquer this terrible disease." Shogen concluded, "MARF has done exceptional work in drawing much-needed attention to malignant mesothelioma, an insidious cancer that affects thousands around the world. Through the annual symposium, MARF also provides a unique, interdisciplinary forum for discussion of the scientific and clinical advances in the treatment of this disease. We salute MARF for their efforts, and will continue to work with them on the mission to find a cure." In addition to Alfacell, other inaugural Pioneer Award recipients included Eli Lilly, Merck, Biogen Idec and Fujirebio Diagnostics. For more information about MARF, a national nonprofit organization dedicated to eradicating mesothelioma as a life-threatening disease, visit http://www.marf.org . About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer, using its proprietary ribonuclease (RNase) technology platform. ONCONASE(R) (ranpirnase), Alfacell's lead investigational drug candidate, has been successfully administered to over 850 patients with a variety of solid tumors, and is currently being evaluated in a Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). For more information, please visit http://www.alfacell.com .
.
